COMMUNIQUÉS West-GlobeNewswire

Purespring to present three posters at the American Society of Nephrology Kidney Week 2025
04/11/2025
New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based therapy delivering the complement factor I to podocytes in patients with IgA nephropathy [...]
Secura Bio Announces Poster Presentation Highlighting Extended Follow Up Analyses from Phase 2 PRIMO Trial at the 2025 American Society of Hematology Meeting
04/11/2025
BERKELEY HEIGHTS, N. J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster [...]
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
04/11/2025
Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026 Novel immunomodulatory regimen designed to reduce calcineurin [...]
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
04/11/2025
MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent [...]
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
04/11/2025
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission [...]
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
04/11/2025
Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation includes data on AL [...]
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
04/11/2025
-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin in 2026 -- BRISBANE, [...]
Lungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy
04/11/2025
STARI will investigate continual diaphragm neurostimulation to improve lung, diaphragm, cardiac and brain function at the earliest stages of mechanical ventilation EXTON, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lungpacer [...]
Zelluna ASA: Disclosure of large shareholding
04/11/2025
In accordance with the Norwegian Securities Trading Act Section 4-3, Inven2 AS ( “Inven2” ) hereby notifies that its ownership interest in Zelluna ASA (“Zelluna”) has fallen below the 10% threshold following the share [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
04/11/2025
COPENHAGEN, Denmark, November 4, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% [...]
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
04/11/2025
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin 1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million. • Organic growth rates by business [...]
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
04/11/2025
Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of [...]
Coloplast A/S - Full-Year Financial Results 2024/25
04/11/2025
2024/25 Full year financial results 1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin 1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and [...]
Zelluna ASA: Disclosure of large shareholding
04/11/2025
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement [...]
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
04/11/2025
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio C3 glomerulopathy (C3G) studies add to body of [...]
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
04/11/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
04/11/2025
November 4, 2025 Q3 2025 Group Highlights Comparable order intake growth 8% Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable sales Income from operations was EUR 330 million Adjusted EBITA [...]
Zelluna ASA – Ex. date
04/11/2025
The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025. This information is published in [...]
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
04/11/2025
Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced [...]

Pages